Literature DB >> 34031573

Enfortumab vedotin is safe and effective.

Peter Sidaway1.   

Abstract

Year:  2021        PMID: 34031573     DOI: 10.1038/s41571-021-00525-w

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

Authors:  Evan Y Yu; Daniel P Petrylak; Peter H O'Donnell; Jae-Lyun Lee; Michiel S van der Heijden; Yohann Loriot; Mark N Stein; Andrea Necchi; Takahiro Kojima; Michael R Harrison; Se Hoon Park; David I Quinn; Elisabeth I Heath; Jonathan E Rosenberg; Joyce Steinberg; Shang-Ying Liang; Janet Trowbridge; Mary Campbell; Bradley McGregor; Arjun V Balar
Journal:  Lancet Oncol       Date:  2021-05-12       Impact factor: 41.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.